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OTTAWA, IDRC -- An unusual example of col1laboration between pub/lie and private 
~ i . I 
enterprise in several countries has led t:o thPl!leftiW~ of ~ simple device 
--~.Ila!;~!-~• .. _ .• ,..~~ .• r;; .. -... :l~-- ,.:~ ••.. ~.' . 
that could save the lives of hundreds of thousands of children in the developing 
world. 
The device is a little red sticker that turns first brown, and then black 
when it gets hot. It is an elegantly simple solution to a problem that has been 
limiting the success of mass-immunization programs in the tropics. Vaccines 
against common childhood diseases are extremely sensitive to heat: the higher 
the temperature, the shorter their effective life. 
A vial of measles vaccine, for example, is good for 54 .days at a 
temperature of 25 degrees Celsius. At 37°C its life is reduced to 12 days at 
most. But there is no visible sign of deterioration, no way in which the health 
worker administering the vaccine can detect the fact that it has expired. Polio 
vaccines deteriorate in a similar fashion. 
This characteristic presents no real problem in an industrialized country, 
where refrigeration is readily available, and vaccines become part of a 11 cold 
chain 11 process from manufacture to vaccination. But in rural areas of developing 
countries the cold chain quickly breaks down when the health worker must travel 
from village to village, often spending days at a time away froin the clinic or 
health centre. 
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The World Health Organization's Expanded Prograrrrne for Immunization 
(WHO/EPI) states bluntly: 11 The biggest stumbling blocks to successful 
immunization programmes are not medical or technical, but the practical 
difficulties arising from field operations .... keeping vaccines safe and 
effective from manufacture to child. 11 
No-one knows for sure just how many children receive useless measles 
vaccinations each year, but estimates vary between 10 million and 16 million. 
Given an estimated mortality rate from measles in the tropics of 10 percent, and 
assuming that 30 percent of unprotected children contract the disease, that 
means at least 300,000 potential child deaths annually, even using the most 
conservative figure, according to Dr Patrick Tam, program officer for the 
Program for Appropriate Technology in Health (PATH). 
Dr Tam, a bio-engineer, is responsible for coordinating the development of 
the little red sticker that promises to solve this problem. The sticker's active 
ingredient is a chemical called 2,4-hexadiyne-1,6-(p-toluenesulfonate), more 
conveniently known as PTS. Exposure to heat causes PTS to polymerize -- a 
shifting of molecules that results in its changing colour. The higher the 
temperature, the more rapid the change. 
The sticker is called a time-temperature indicator. It was devised 
initially by the Allied Corporation in the US. But Allied estimated it would 
cost them from US$4 million to US$5 million to develop the indicator for 
mass-production, and that they would be unable to recover their investment. So 
Allied approached WHO with their invention -- and that was when PATH heard about 
it. 
The small, Seattle-based non-profit agency has very little cash, but it has 
a good reputation, and excellent contacts. In short order, Dr Tani developed a 
proposal for a one-year feasibility study of Allied's prototype indicator, and 
obtained 95 percent of the funding needed from the Edna McConnell Clark 
Foundation, of New York, and Canada's International Development Research Centre 
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(IDRC). The total cost of this study was just Cdn$168,900. 
One of the first questions to be resolved was the safety of the product, 
both for health workers in the field and for those involved in the production 
process. Taxi co logy studies showed possible harmful effects from contact with 
PTS. To overcome this problem, a clear plastic coating was developed to prevent 
direct contact with the chemical, and production workers were instructed to wear 
protective gloves and masks. 
With safety assured, the PATH researchers began detailed testing. They 
found that the indicators could be manufactured to closely parallel the rate of 
degradation of measles vaccines obtained from major manufacturers, and that they 
could be manufactured to match the WHO/EPI recommended standard of seven days 
maximum exposure at 37°C. Working closely with the staff of WHO/EPI, the 
researchers used this same technology to develop a 11management indicator 11 • This 
is a label for use on large batches of vaccine. It incorporates four PTS dots 
that change colour in sequence according to the extent of exposure the carton 
containing the vaccine vials has undergone. Thus managers can see at a glance 
which batches must be used first, or have already expired. The label also has 
space for a complete shipping history of each carton. 
The single-vial indicators are attached to the tops of vials so that health 
workers cannot fail to notice if the red colour has changed to brownish-black. 
Successful preliminary field tests were carried out in Mexico, the Philippines, 
and Indonesia. Conn aught Laboratories, of Toronto, who are collaborating with 
PATH on the adaptation of the indicator for use with polio vaccines, carried out 
additional field tests in Pakistan at their own expense. More tests are also 
being conducted in the People's Republic of China after the Chinese government 
requested a batch of the prototype indicators for testing with their locally 
manufactured vaccines. 
The second phase of the project, now nearing completion, cost a further 
Cdn$268,000, provided by the two original donors plus Oxfam of the United 
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Kingdom, and also involves another Canadian vaccine manufacturer, the Institut 
Armand Frappier. More extensive field testing is being carried out in 11 
countries of Africa, Asia and Latin America in this phase with additional 
funding from WHO/EPI. The tests involve evaluation by health workers and others 
of the design of the indicators and the instructional materials that have been 
prepared for use with them. The exercise will also help to introduce the concept 
of visual indicators into many ministries of health. PATH is collaborating 
closely at this stage with WHO/EPI and other major agencies, such as UNICEF, to 
ensure successful introduction of the indicators as soon as they become 
avai 1ab1 e. 
The tech~ical problems to be overcome in order to bring the indicators to 
mass-production are considerable, but not insurmountable according to Dr Tam. 
And mass-production is essential, he says, to keep the eventual cost of the 
_indicators as low as possible. 
The PTS compound is to be formulated into an ink suitable for printing 
presses, and there is machinery to be developed for mass application of the 
indicators on individual vials and on shipping cartons. There are manuals to be 
prepared as a first step to the transfer of the technology. And finally there is 
an agreement on royalties to be finalized with ACC, who still hold the patent on 
the invention until the early 1990s. 
If all continues to go well, mass-product ion could begin as early as 1983, 
says Dr Tam, and health workers around the world will soon become accustomed to 
looking for that little red sticker that will tell them that this vaccination 
will give a child protection. 
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